메뉴 건너뛰기




Volumn 39, Issue 11, 2019, Pages 1067-1075

Comprehensive Real-World Assessment of Marketed Medications to Guide Parkinson’s Drug Discovery

Author keywords

[No Author keywords available]

Indexed keywords

ARMODAFINIL; DIPHENHYDRAMINE; ISRADIPINE; METHYLPHENIDATE; MODAFINIL; SALBUTAMOL; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

EID: 85070733718     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-019-00830-4     Document Type: Article
Times cited : (21)

References (27)
  • 1
    • 85055021376 scopus 로고    scopus 로고
    • Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    • Dorsey ER. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53.
    • (2018) Lancet Neurol , vol.17 , Issue.11 , pp. 939-953
    • Dorsey, E.R.1
  • 2
    • 84941793151 scopus 로고    scopus 로고
    • precompetitive data sharing as a catalyst to address unmet needs in Parkinson’s disease
    • PID: 26406139
    • Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, et al. precompetitive data sharing as a catalyst to address unmet needs in Parkinson’s disease. J Parkinsons Dis. 2015;5(3):581–94.
    • (2015) J Parkinsons Dis , vol.5 , Issue.3 , pp. 581-594
    • Stephenson, D.1    Hu, M.T.2    Romero, K.3    Breen, K.4    Burn, D.5    Ben-Shlomo, Y.6
  • 3
    • 85046011853 scopus 로고    scopus 로고
    • Targeted therapies for Parkinson’s disease: from genetics to the clinic
    • Sardi SP, Cedarbaum JM, Brundin P. Targeted therapies for Parkinson’s disease: from genetics to the clinic. Mov Dis. 2018;33(5):684–96.
    • (2018) Mov Dis , vol.33 , Issue.5 , pp. 684-696
    • Sardi, S.P.1    Cedarbaum, J.M.2    Brundin, P.3
  • 4
    • 78751688048 scopus 로고    scopus 로고
    • Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership
    • PID: 21041580
    • Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600–6.
    • (2010) Ann Intern Med , vol.153 , Issue.9 , pp. 600-606
    • Stang, P.E.1    Ryan, P.B.2    Racoosin, J.A.3    Overhage, J.M.4    Hartzema, A.G.5    Reich, C.6
  • 5
    • 84952053307 scopus 로고    scopus 로고
    • Observational health data sciences and informatics (OHDSI): opportunities for observational researchers
    • PID: 26262116
    • Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574–8.
    • (2015) Stud Health Technol Inform , vol.216 , pp. 574-578
    • Hripcsak, G.1    Duke, J.D.2    Shah, N.H.3    Reich, C.G.4    Huser, V.5    Schuemie, M.J.6
  • 6
    • 85029541597 scopus 로고    scopus 로고
    • β2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease
    • COI: 1:CAS:528:DC%2BC2sXhtl2kurrP, PID: 28860381
    • Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. β2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891–8.
    • (2017) Science , vol.357 , Issue.6354 , pp. 891-898
    • Mittal, S.1    Bjornevik, K.2    Im, D.S.3    Flierl, A.4    Dong, X.5    Locascio, J.J.6
  • 7
    • 85050009917 scopus 로고    scopus 로고
    • Network-based approach to prediction and population-based validation of in silico drug repurposing
    • PID: 30002366
    • Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):2691.
    • (2018) Nat Commun , vol.9 , Issue.1 , pp. 2691
    • Cheng, F.1    Desai, R.J.2    Handy, D.E.3    Wang, R.4    Schneeweiss, S.5    Barabasi, A.L.6
  • 8
    • 84892945980 scopus 로고    scopus 로고
    • Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system
    • PID: 24166227
    • Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S95–106.
    • (2013) Drug Saf , vol.36 , pp. S95-S106
    • Ryan, P.B.1    Schuemie, M.J.2    Madigan, D.3
  • 9
    • 84892948635 scopus 로고    scopus 로고
    • A comparison of the empirical performance of methods for a risk identification system
    • PID: 24166231
    • Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143–58.
    • (2013) Drug Saf , vol.36 , pp. S143-S158
    • Ryan, P.B.1    Stang, P.E.2    Overhage, J.M.3    Suchard, M.A.4    Hartzema, A.G.5    DuMouchel, W.6
  • 10
    • 84892916187 scopus 로고    scopus 로고
    • Evaluating performance of risk identification methods through a large-scale simulation of observational data
    • PID: 24166233
    • Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36(Suppl 1):S171–80.
    • (2013) Drug Saf , vol.36 , pp. S171-S180
    • Ryan, P.B.1    Schuemie, M.J.2
  • 11
    • 84892947582 scopus 로고    scopus 로고
    • Empirical performance of the case-control method: lessons for developing a risk identification and analysis system
    • PID: 24166225
    • Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73–82.
    • (2013) Drug Saf , vol.36 , pp. S73-S82
    • Madigan, D.1    Schuemie, M.J.2    Ryan, P.B.3
  • 12
    • 84908292293 scopus 로고    scopus 로고
    • A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends
    • PID: 25323155
    • Butt DA, Tu K, Young J, Green D, Wang M, Ivers N, et al. A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends. Neuroepidemiology. 2014;43(1):28–37.
    • (2014) Neuroepidemiology , vol.43 , Issue.1 , pp. 28-37
    • Butt, D.A.1    Tu, K.2    Young, J.3    Green, D.4    Wang, M.5    Ivers, N.6
  • 13
    • 0041876133 scopus 로고    scopus 로고
    • Measuring inconsistency in meta-analyses
    • PID: 192859
    • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
    • (2003) BMJ , vol.327 , Issue.7414 , pp. 557-560
    • Higgins, J.P.1    Thompson, S.G.2    Deeks, J.J.3    Altman, D.G.4
  • 14
    • 79955544813 scopus 로고    scopus 로고
    • Interpretation of random effects meta-analyses
    • PID: 21310794
    • Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
    • (2011) BMJ , vol.342 , pp. d549
    • Riley, R.D.1    Higgins, J.P.T.2    Deeks, J.J.3
  • 15
    • 84881589353 scopus 로고    scopus 로고
    • Evaluating the impact of database heterogeneity on observational study results
    • PID: 23648805
    • Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178(4):645–51.
    • (2013) Am J Epidemiol , vol.178 , Issue.4 , pp. 645-651
    • Madigan, D.1    Ryan, P.B.2    Schuemie, M.3    Stang, P.E.4    Overhage, J.M.5    Hartzema, A.G.6
  • 16
    • 85055879668 scopus 로고    scopus 로고
    • β2-adrenoreceptor medications and risk of Parkinson disease
    • COI: 1:CAS:528:DC%2BC1cXitlGgsbjE, PID: 30225948
    • Searles Nielsen S, Gross A, Camacho-Soto A, Willis AW, Racette BA. β2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84(5):683–93.
    • (2018) Ann Neurol , vol.84 , Issue.5 , pp. 683-693
    • Searles Nielsen, S.1    Gross, A.2    Camacho-Soto, A.3    Willis, A.W.4    Racette, B.A.5
  • 17
    • 84940392979 scopus 로고    scopus 로고
    • Feasibility and utility of applications of the common data model to multiple, disparate observational health databases
    • PID: 25670757
    • Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553–64.
    • (2015) J Am Med Inform Assoc , vol.22 , Issue.3 , pp. 553-564
    • Voss, E.A.1    Makadia, R.2    Matcho, A.3    Ma, Q.4    Knoll, C.5    Schuemie, M.6
  • 18
    • 85021636304 scopus 로고    scopus 로고
    • Nicotine from cigarette smoking and diet and Parkinson disease: a review
    • PID: 28680589
    • Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Transl Neurodegener. 2017;6:18.
    • (2017) Transl Neurodegener , vol.6 , pp. 18
    • Ma, C.1    Liu, Y.2    Neumann, S.3    Gao, X.4
  • 20
    • 77953185520 scopus 로고    scopus 로고
    • The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors
    • COI: 1:CAS:528:DC%2BC3cXpsFGjtrw%3D, PID: 20590599
    • Baker JG. The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010;160(5):1048–61.
    • (2010) Br J Pharmacol , vol.160 , Issue.5 , pp. 1048-1061
    • Baker, J.G.1
  • 21
    • 1442349847 scopus 로고    scopus 로고
    • Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells
    • COI: 1:CAS:528:DC%2BD2cXhtVygtbc%3D, PID: 14730417
    • Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes–characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(2):151–9.
    • (2004) Naunyn Schmiedebergs Arch Pharmacol , vol.369 , Issue.2 , pp. 151-159
    • Hoffmann, C.1    Leitz, M.R.2    Oberdorf-Maass, S.3    Lohse, M.J.4    Klotz, K.N.5
  • 22
    • 84891699606 scopus 로고    scopus 로고
    • Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis
    • PID: 24312590
    • Sheng P, Hou L, Wang X, Wang X, Huang C, Yu M, et al. Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis. PLoS One. 2013;8(12):e81802.
    • (2013) PLoS One , vol.8 , Issue.12
    • Sheng, P.1    Hou, L.2    Wang, X.3    Wang, X.4    Huang, C.5    Yu, M.6
  • 23
    • 84951951974 scopus 로고    scopus 로고
    • Catecholaminergic based therapies for functional recovery after TBI
    • COI: 1:CAS:528:DC%2BC2MXitVyqs77F, PID: 26711850
    • Osier ND, Dixon CE. Catecholaminergic based therapies for functional recovery after TBI. Brain Res. 2016;1640(Pt A):15–35.
    • (2016) Brain Res , vol.1640 , pp. 15-35
    • Osier, N.D.1    Dixon, C.E.2
  • 24
    • 84885368200 scopus 로고    scopus 로고
    • Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions
    • Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol. 2013;7(4):139.
    • (2013) Front Neurol , vol.7 , Issue.4 , pp. 139
    • Wisor, J.1
  • 25
    • 85024403534 scopus 로고    scopus 로고
    • Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice
    • PID: 28521299
    • Wang QM, Xu YY, Liu S, Ma ZG. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. Oncotarget. 2017;8(29):47284–95.
    • (2017) Oncotarget , vol.8 , Issue.29 , pp. 47284-47295
    • Wang, Q.M.1    Xu, Y.Y.2    Liu, S.3    Ma, Z.G.4
  • 26
    • 85074541588 scopus 로고    scopus 로고
    • A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): baseline characteristics and study update [abstract no. P2.039]
    • Simuni T, Holloway R, Oakes D, Biglan K, Lungu C. A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): baseline characteristics and study update [abstract no. P2.039]. Neurology. 2018;90(15 Suppl):P2.39.
    • (2018) Neurology , vol.90 , pp. P2.39
    • Simuni, T.1    Holloway, R.2    Oakes, D.3    Biglan, K.4    Lungu, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.